• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidental treatment of granulomatosis with polyangiitis with a Janus Kinase inhibitor in a patient undergoing alopecia treatment.

作者信息

Mendez Daniela, Xiang Laura, Bergfeld Wilma

机构信息

Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio.

出版信息

JAAD Case Rep. 2025 Jul 22;64:141-143. doi: 10.1016/j.jdcr.2025.06.046. eCollection 2025 Oct.

DOI:10.1016/j.jdcr.2025.06.046
PMID:40948684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12423697/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7949/12423697/f14121f96ac2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7949/12423697/f14121f96ac2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7949/12423697/f14121f96ac2/gr1.jpg

相似文献

1
Incidental treatment of granulomatosis with polyangiitis with a Janus Kinase inhibitor in a patient undergoing alopecia treatment.
JAAD Case Rep. 2025 Jul 22;64:141-143. doi: 10.1016/j.jdcr.2025.06.046. eCollection 2025 Oct.
2
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
3
Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.斑秃当前发作的持续时间可预测巴瑞替尼对日本斑秃患者的疗效：一项单中心回顾性研究
J Dermatolog Treat. 2025 Dec;36(1):2555684. doi: 10.1080/09546634.2025.2555684. Epub 2025 Sep 7.
4
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.在两项III期试验中，巴瑞替尼治疗重度斑秃成人患者长达4年（中位治疗时间2.3年）的安全性。
Am J Clin Dermatol. 2025 Apr 11. doi: 10.1007/s40257-025-00932-0.
5
Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study.巴瑞替尼治疗重度斑秃患者的安全性概况：一项前瞻性研究。
Int J Dermatol. 2025 Jul;64(7):1242-1245. doi: 10.1111/ijd.17732. Epub 2025 Mar 21.
6
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.不同 JAK 抑制剂治疗斑秃的疗效和安全性：网状荟萃分析。
Front Immunol. 2023 Apr 17;14:1152513. doi: 10.3389/fimmu.2023.1152513. eCollection 2023.
7
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.最初接受4毫克巴瑞替尼治疗的重度头皮斑秃患者减量滴定的结果：来自BRAVE-AA2研究的第152周数据。
J Am Acad Dermatol. 2025 Feb;92(2):299-306. doi: 10.1016/j.jaad.2024.09.072. Epub 2024 Oct 22.
8
CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.CS12192通过选择性靶向JAK3/JAK1/TBK1逆转斑秃。
Adv Biol (Weinh). 2025 Aug;9(8):e2400769. doi: 10.1002/adbi.202400769. Epub 2025 Feb 28.
9
Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study.约旦患者中 Janus 激酶抑制剂治疗脱发的疗效：一项回顾性队列研究。
Cureus. 2025 May 18;17(5):e84321. doi: 10.7759/cureus.84321. eCollection 2025 May.
10
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.成人斑秃治疗新药的系统评价：Janus 激酶抑制剂、生物制剂和磷酸二酯酶 4 抑制剂。
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):666-679. doi: 10.1111/jdv.18810. Epub 2022 Dec 22.

本文引用的文献

1
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.管理与 JAK 抑制剂相关的心血管和癌症风险。
Drug Saf. 2023 Nov;46(11):1049-1071. doi: 10.1007/s40264-023-01333-0. Epub 2023 Jul 25.
2
Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series.托法替布单药治疗皮肤型结节性多动脉炎：病例系列
Rheumatol Adv Pract. 2023 Jun 9;7(2):rkad049. doi: 10.1093/rap/rkad049. eCollection 2023.
3
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.
Janus 激酶抑制剂治疗巨细胞动脉炎的临床经验和安全性：来自瑞典的回顾性病例系列研究。
Front Immunol. 2023 May 25;14:1187584. doi: 10.3389/fimmu.2023.1187584. eCollection 2023.
4
Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis.
J Rheumatol. 2023 Aug;50(8):1088-1089. doi: 10.3899/jrheum.221219. Epub 2023 Mar 15.
5
Molecular dissection of Janus kinases as drug targets for inflammatory diseases.Janus 激酶作为炎症性疾病药物靶点的分子剖析。
Front Immunol. 2022 Dec 8;13:1075192. doi: 10.3389/fimmu.2022.1075192. eCollection 2022.
6
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.用于治疗肿瘤性疾病和炎症性疾病的Janus激酶（JAK）抑制剂。
Pharmacol Res. 2022 Sep;183:106362. doi: 10.1016/j.phrs.2022.106362. Epub 2022 Jul 22.
7
A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.对Janus激酶抑制剂治疗大血管血管炎的临床和临床前证据的系统评价。
Clin Rheumatol. 2022 Jan;41(1):33-44. doi: 10.1007/s10067-021-05973-4. Epub 2021 Nov 3.
8
Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study.托法替布治疗抗中性粒细胞胞浆抗体相关性血管炎：一项初步研究。
Ann Rheum Dis. 2021 Dec;80(12):1631-1633. doi: 10.1136/annrheumdis-2021-220484. Epub 2021 Aug 6.
9
Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report.托法替尼治疗难治性皮肤白细胞碎裂性血管炎：一例报告。
Front Immunol. 2021 Jun 24;12:695768. doi: 10.3389/fimmu.2021.695768. eCollection 2021.
10
Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.Janus 激酶（JAKs）：自身免疫性疾病和骨髓增生性疾病的有效治疗靶点。
Eur J Med Chem. 2020 Apr 15;192:112155. doi: 10.1016/j.ejmech.2020.112155. Epub 2020 Feb 18.